Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

New door-to-door pharmacy delivery app promises to make London life less painful

It’s like shopping at Boots on your phone with the meds biked to your home in minutes.

Evening Standard

Pharmacy contraceptive pill trial a 'band-aid solution'

The health minister welcomes a proposed trial to allow pharmacists to prescribe the contraceptive pill but doctors' groups have criticised the move.

AAP

Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease Test

Valneva stock plummeted Friday after Pfizer said it will drop roughly half of the participants enrolled in their Lyme disease vaccine study.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

The big business of clogged arteries

Medtronic, the world’s largest medical device company, allegedly "groomed" doctors to overuse its vascular products

Salon

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

The Independent UK

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The No. 1 Pharma Stock to Buy for the Long Haul

Despite lingering macro disruptions, Street analysts expect pharma stock Pfizer (PFE) to gain double digits in the near term. Moreover, it pays a reliable dividend. Given its robust fundamentals, I think PFE might be an ideal buy for the long haul. Keep reading.

StockNews.com

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment.

Investors Business Daily

FDA panel weighs moving opioid antidote over the counter

U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication

The Independent UK

Prepping for a new post-Roe reality

A decision on a lawsuit in Texas could lead to nationwide mifepristone ban

Salon

Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount

Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.

Investors Business Daily

The administration's next crack at lower drug prices

The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs.

Axios

Edinburgh-based health tech company Clevermed acquired by hospital software specialist System C

Move will support growth of flagship product BadgerNet,

Insider UK

Get all your
news in one place.

100’s of premium titles.
One news app.

AAP

CSL grows first-half profit 10pct to $2.6 billion

CSL has beaten first-half earnings expectations thanks to its vaccine business and contributions from its new iron deficiency therapy company.

Investors Business Daily

Biotech's Drug Pipeline Expands From Melanoma To Other Cancers

Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March.

StockNews.com

The Best Stock to Invest $1,000 in Right Now

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

Investors Business Daily

Moderna Stock Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Axios

40 million would lose abortion access if court blocks pill, study shows

163% more women would lose access to abortion care if the FDA's approval of mifepristone is revoked.

The Guardian - UK

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

Chicago Sun-Times

Centene Corp. settles for $215 million on California Medicaid overbilling accusations

More than 20 states are investigating or have investigated Centene’s Medicaid pharmacy billing. The company also has agreed to pay settlements to at least 16 other states, including Illinois and Indiana.

Newsroom.co.nz

Pharmac to get one-time $66m boost

The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash injection, according to documents reviewed by Newsroom.

Investors Business Daily

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

AbbVie Rises As Lagging Profit Outlook Better Than Feared In Humira Battle Year

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook.

1 … 45 46 47 48

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.